Respimer® Hygiene-Prevention -Baby, kids, adults
Device1-3 seconds spray in each nostril,
- 4 to 6 times a day, in treatment of nasal symptoms.
- 1 to 2 times a day, in hygiene and prevention
NCT Number: NCT07262450
The purpose of this post-market clinical investigation is to assess in a real-life setting, the effectiveness, usage, tolerance, safety and satisfaction of 4 isotonic and hypertonic seawater-based CE-marked nasal sprays.
The main questions it aims to answer are:
* Efficacy, * Safety, * Usage, * Satisfaction, in real-life usage among infants, children, adults and pregnant or breastfeeding women suffering from acute and chronic sinonasal pathologies. The 4 medical devices under investigation will be used in accordance with their intended use, target populations and medical indications.
Interested in participating?
Request Info15 day and older
All sexes
Interventional
Not applicable
CHU Bordeaux, Bordeaux, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Non-inclusion criteria:
1-3 seconds spray in each nostril,
1-2 seconds spray in each nostril,
Baby (2 months+): 1-3 seconds spray in each nostril, up to 3 times a day Children (2 y+) and adults: 1-3 seconds spray in each nostril, up to 6 times a day
1 second spray in each nostril, 2-3 times a day.
Time frame: From Day 0 to Day 5 (acute indications: URTI, COVID-19, bronchiolitis) From Day 0 to Day 14 (chronic indications: allergic rhinitis, chronic rhinosinusitis, post-surgery)
Change from baseline in nasal symptom intensity following initiation of nasal wash, based on the modified SNOT-22 rhinologic score. 6-modalities intensity Likert scale: 0=No problem; 1= Very mild problem; 2=Mild or slight problem; 3= Moderate problem; 4=Severe problem; 5=Problem as bad as it can be.
Time frame: From Day 0 to Day 14
Daily change from baseline in individual symptoms intensity. 6-modalities intensity Likert scale.
Time frame: From Day 0 to Day 14
Daily change from baseline in additional extra nasal symptoms intensity. 6-modalities intensity Likert scale.
Time frame: From Day 0 to Day 14
Daily change from baseline in eyes symptoms intensity. Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ): 6-modalities scale.
Time frame: From Day 0 to Day 14
Proportion of patients presenting a daily change in symptoms intensity; Modified SNOT-22: 6-modalities intensity Likert scale. Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ): 6-modalities scale
Time frame: From Day 0 to Day 14
Daily change from baseline in the global modified SNOT-22 score and domains
Time frame: From Day 0 to Day 14
Daily change from baseline in sneezing frequency. 5-modalities sneezing frequency scale
Time frame: From Day 0 to Day 14
Daily change from baseline in nose blowing frequency. 6-modalities nose blowing frequency scale
Time frame: From Day 0 to Day 14
Daily change from baseline in cough frequency. 6-modalities Cough Symptom Score
Time frame: From Day 0 to Day 14
Daily evolution of individual symptoms relief. Symptoms relief scale: 7-modalities scale
Time frame: From Day 0 to Day 14
Proportion of patients reporting a daily symptom relief. Symptoms relief scale: 7-modalities scale
Time frame: From Day 0 to Day 14
Number of days until first symptom relief. Symptoms relief scale: a 7-modalities scale
Time frame: From Day 0 to Day 14
Daily change from baseline in nasal breathing difficulty. Nasal breathing difficulty scale: 6-modalities scale
Time frame: From Day 0 to Day 14
Time to perceived improvement of nasal breathing. Nasal breathing scale: 7-modalities rating scale
Time frame: From Day 0 to Day 14
Duration of improved nasal breathing. Improved nasal breathing scale: 7-modalities questionnaire
Time frame: From Day 0 to Day 14
Daily average time between two consecutive nasal washes. Open question whose unit of measurement is in hours
Time frame: From Day 0 to Day 14
Daily change from baseline in nose blowing/removal of secretions Easiness to blow the nose/remove secretions scale: 5-modalities rating scale
Time frame: From Day 0 to Day 14
Daily change from baseline in quality of nasal secretions. Quality of nasal secretions scale: 4-modalities rating scale
Time frame: From Day 0 to Day 14
Daily change from baseline in subjects' quality of life. QOL items of the modified SNOT-22 questionnaire: 6-modalities intensity Likert scale
Time frame: From Day 0 to Day 14
Daily change from baseline in loss of energy. 4-modalities rating energy scale
Time frame: From Day 0 to Day 14
Daily change from baseline in symptoms interference with daily activities. Symptom interference scale: 5-modalities rating scale
Time frame: From Day 0 to Day 14
Daily change from baseline in feeding difficulties. Babies's feeding difficulty scale: 0-10 VAS scale
Time frame: From Day 0 to Day 14
Daily change from baseline in cries frequency, irritability, comfort and wellbeing, overall behaviour.
Baby and young child quality of life scale: 6-modalities rating scale.
Time frame: From Day 0 to Day 14
Daily change from baseline in family/parental quality of life. Family/parental quality of life scale: 6-modalities rating scale
Time frame: From Day 15 to 3 months
Number and proportion of subjects with nasal symptoms. Modified SNOT-22 self-questionnaire: 6-modalities intensity Likert scale
Time frame: From Day 15 to 3 months
Number of nasal symptoms per subject. Modified SNOT-22 self-questionnaire: 6-modalities intensity Likert scale
Time frame: From Day 15 to 3 months
Evolution of nasal symptoms intensity. SNOT-22 self-questionnaire: 6-modalities intensity Likert scale
Time frame: From Day 15 to 3 months
Evolution of sneezing frequency. 5-modalities sneezing frequency scale
Time frame: From Day 15 to 3 months
Evolution of nose blowing/Need to rub the nose frequency. 6-modalities nose blowing frequency scale
Time frame: From Day 15 to 3 months
Number and proportion of subjects with extra-nasal symptoms. Modified SNOT-22 self questionnaire: 6-modalities scale
Time frame: From Day 15 to 3 months
Number of extra-nasal symptoms per subject. Modified SNOT-22 self questionnaire: 6-modalities scale
Time frame: From Day 15 to 3 months
Evolution of extra-nasal symptoms intensity. Modified SNOT-22 self questionnaire: 6-modalities scale
Time frame: From Day 15 to 3 months
Evolution of eyes symptoms intensity for allergic rhinitis sufferers. Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ):7-point Likert scale
Time frame: From Day 15 to 3 months
Evolution of modified SNOT-22 domains. Modified SNOT-22 self-questionnaire: 6-modalities scale
Time frame: From Day 15 to 3 months
Evolution of modified SNOT-22 global score. Modified SNOT-22 self-questionnaire: 6-modalities scale
Time frame: From Day 15 to 3 months
Evolution of cough, snoring, wake up at night. Snoring, wake up at night (due to symptoms), cough frequency scale: 7-modalities rating scale
Time frame: From Day 15 to 3 months
Number and proportion of subjects with acute respiratory infection. Multiple-choice question regarding acute respiratory infection including the start date of the symptoms.
Time frame: From Day 15 to 3 months
Number and proportion of subjects with acute allergic rhinitis episodes (for allergic rhinitis sufferers).
Open question whose unit of measurement is in number of episodes.
Time frame: From Day 15 to 3 months
Number and proportion of subjects with asthma episodes/exacerbations (for allergic rhinitis sufferers).
Open question whose unit measurement is in number of episodes.
Time frame: From Day 15 to 3 months
Evolution of nasal breathing score. Nasal breathing difficulty scale: 6-modalities scale
Time frame: From Day 15 to 3 months
Evolution in modified SNOT-22 quality of life items. Modified SNOT-22 self-questionnaire: 6-modalities intensity Likert scale
Time frame: From Day 15 to 3 months
Evolution in loss of energy. 4-modalities rating energy scale
Time frame: From Day 15 to 3 months
Evolution of well-being and global health status. 0-10 VAS scale
Time frame: From Day 15 to 3 months
Evolution of symptom interference with daily activities. 5-modalities rating scale
Time frame: From Day 15 to 3 months
Evolution in practical problems (inconvenience of having to carry tissues/hankerchiefs, need to rub nose/eye, need to blow your nose repeatedly), for allergic rhinitis sufferers.
6 modalities Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scale.
Time frame: From Day 15 to 3 months
Number of days with sickness / nasal symptoms. Open question whose unit of measurement is in number of days
Time frame: From Day 15 to 3 months
Number and percentage of subjects with sickness days . Open question whose unit of measurement is in number of days
Time frame: From Day 15 to 3 months
Number of missed days (work, school, daycare). Open question whose unit of measurement is in number of days
Time frame: From Day 15 to 3 months
Number and percentage of subjects with missed days (work, school, daycare). Open question whose unit of measurement is in number of days
Time frame: From Day 15 to 3 months
Number of days of parental absence (work activities) due to baby/child's disease.
Open question whose unit of measurement is in number of days
Time frame: From Day 15 to 3 months
Number and percentage of parents with missed days (work, activities). Open question whose unit of measurement is in number of days
Time frame: From Day 15 to 3 months
Number of days with impaired family/parental quality of life. Family/parental quality of life scale : 6-modalities rating scale
Time frame: From Day 15 to 3 months
Number and percentage of parents/family with impaired quality of life. Family/parental quality of life scale: 6 modalities rating scale
Time frame: From Day 15 to 3 months
Number and percentage of subjects with intake of medications. Questions about name of the treatment, route of administration and number of days of use for each treatement
Time frame: From Day 15 to 3 months
Number of days with intake of medications. Question about name of the treatment, route of administration and number of days of use for each treatement
Time frame: From Day 15 to 3 months
Number and percentage of subjects in control group with re-introduction of nasal wash.
Question about the name and format of the nasal wash product and number of days of use.
Time frame: From Day 15 to 3 months
Evolution of allergic rhinitis treatment for allergic rhinitis sufferers. 3-modalities scale
Time frame: From Day 15 to 3 months
Number and percentage of subjects with severe symptoms intensity. Modified SNOT-22 self-questionnaire: 6-modalities intensity Likert scale
Time frame: From Day 15 to 3 months
Number and percentage of subjects with severe extra-nasal symptoms intensity. Modified SNOT-22 self-questionnaire: 6-modalities intensity Likert scale
Time frame: From Day 15 to 3 months
Number and percentage of subjects with severe eyes symptom intensity. Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scale: 7-point Likert scale
Time frame: From Day 15 to 3 months
Number and percentage of subjects with occurence of complications. Multiple-choice question.
Time frame: From Day 15 to 3 months
Evolution of asthma symptoms frequency for asthma sufferers. 7-modalities frequency scale
Time frame: From Day 15 to 3 months
Number and percentage of subjects with asthma episodes/exacerbation for asthma sufferers.
Open question
Time frame: From Day 15 to 3 months
Evolution of asthma symptoms intensity for asthma sufferers. 7-modalities scale
Time frame: From Day 15 to 3 months
Number and percentage of subjects consulting a HCP. Collection of unplanned HCP consultations because of nasal/respiratory symptoms
Time frame: From Day 15 to 3 months
Number and percentage of hospitalized subjects. Collection of hospitalizations due to nasal/respiratory symptoms
Time frame: From Day 15 to Month 3
Time to perceived improvement of nasal breathing. 7 modalities rating scale.
Time frame: From Day 15 to Month 3
Duration of improved nasal breathing. 7-modalities questionnaire
Time frame: From Day 15 to Month 3
Daily average time between two consecutive nasal washes. Open question whose unit of measurement is in hours
Time frame: From Day 15 to Month 3
Number and percentage of subjects with improved effectiveness of their usual allergic rhinitis treatment.
7-modalities questionnaire
Time frame: From Day 0 to Month 3
Number of nasal wash per day and Number of days of use per week . 8-modalities posology questionnaire
Time frame: From Day 0 to Month 3
Moments of use of the nasal spray during the day. 7-modalities multiple choice question
Time frame: From Day 0 to Month 3
Moments of use versus medications. Co-usage questionnaire.
Time frame: From Day 15 to Month 3
Occasion of use during the prevention phase. Multiple-choice question
Time frame: From Day 0 to Month 3
Complementary usage of a baby nasal aspirator. 7-modalities frequency scale
Time frame: From Day 0 to Month 3
Child's autonomy in using the nasal spray. Multiple-choice question
Time frame: From Day 0 to Month 3
Number and percentage of subjects satisfied with the use of the nasal spray. 5-modalities satisfaction scale.
Time frame: From Day 0 to Month 3
Perceived sensation after application. 5-modalities sensory scale.
Time frame: From Day 0 to Month 3
Global perceived effectiveness of the nasal spray. 6-modalities rating scale
Time frame: From Day 0 to Month 3
Practicality of the product, easiness to use. 6-modalities technical performance agreement scale.
Time frame: From Day 0 to Month 3
Number and percentage of subjects with willingness to reuse, willingness to recommend the nasal spray.
4-modalities scale
Time frame: From Day 0 to Month 3
Usefulness of the educational content (tutorial and tips). Multiple choice satisfaction questionnaire.
Time frame: From Day 0 to Month 3
Evolution of tolerance to the nasal spray. 4-modalities scale.
Time frame: From Day 0 to Month 3
Number and percentage of incidents reported during the clinical investigation. Number and percentage of subjects reporting incidents during the clinical investigation.
Collection of incidents and adverse events (nature, dates of occurrence and evolution).
Contact information is provided by the study sponsor or research team.
Laboratoire de la Mer
Industry
Real-word Study to Assess Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms
Acronym: SeaBridge
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07157111
COVID - 19, COVID-19
Wuhan, Hubei, China
View Trial DetailsNCT06104332
Allergic Rhinitis, Hypersensitivity
Honfleur, France
View Trial DetailsNCT07642648
Common Cold, Infections
View Trial DetailsNCT07498127
URTI
Xuhui, Shanghai Municipality, China
View Trial Details